Defining response to anti-VEGF therapies in neovascular AMD
Defining response to anti-VEGF therapies in neovascular AMD
About this item
Full title
Author / Creator
Amoaku, W M , Chakravarthy, U , Gale, R , Gavin, M , Ghanchi, F , Gibson, J , Harding, S , Johnston, R L , Kelly, S , Lotery, A , Mahmood, S , Menon, G , Sivaprasad, S , Talks, J , Tufail, A and Yang, Y
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
The introduction of anti-vascular endothelial growth factor (anti-VEGF) has made significant impact on the reduction of the visual loss due to neovascular age-related macular degeneration (n-AMD). There are significant inter-individual differences in response to an anti-VEGF agent, made more complex by the availability of multiple anti-VEGF agents...
Alternative Titles
Full title
Defining response to anti-VEGF therapies in neovascular AMD
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4469673
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4469673
Other Identifiers
ISSN
0950-222X
E-ISSN
1476-5454
DOI
10.1038/eye.2015.48
